Genome-Scale Variant Interpretation

Automated Radiation Dose Estimation

Mission Statement

MutationForecaster® (mutationforecaster.com) is Cytognomix’s patented web-portal for analysis of all types of mutations – coding and non-coding- including interpretation, comparison and management of genetic variant data. It’s a fully automated genome interpretation solution for research, translational and clinical labs.

Run our world-leading genome interpretation software on your exome, gene panel, or complete genome (Shannon transcription factor and splicing pipelines, ASSEDA, Veridical) with the Cytognomix User Variation Database and  Variant Effect Predictor.  With our integrated suite of software products, analyze coding, non-coding, and copy number variants, and compare new results with existing or your own database.  Select predicted mutations  by phenotype using articles with CytoVisualization Analytics.  With Workflows,  automatically perform end-to-end analysis with all of our software products.  Download an 1 page overview of MutationForecaster® (link)

Subscribe and analyze your own data via the cloud or… Don’t want to run your own analyses on MutationForecaster®? Let us do it for you with our Bespoke Analysis Service.

Experience our suite of genome interpretation products through a free trial of MutationForecaster®. Once you register, we provide datasets from our peer-reviewed publications to evaluate these software tools.

Automated radiation biodosimetry

Ionizing radiation produces characteristic chromosome changes. The altered chromosomes  are known as dicentric chromosomes [DCs]). DC biodosimetry is approved by the IAEA for occupational radiation exposure, radiation emergencies, or monitoring long term exposures.  The DC assay can also monitor effects of interventional radiation therapies.

Cytognomix has developed  a novel approach to find DCs (TBME).  The Automated Dicentric Chromosome Identifier and Dose Estimator (ADCI) software  works on multiple platforms and uses images produced by any of the existing automated metaphase capture systems found in most cytogenetic laboratories. ADCI is now available for for trial or  purchase (link).  Or contact us for details (pricing).

ADCI* uses machine learning to distinguish monocentric and dicentric chromosomes (Try the Dicentric Chromosome Identifier web app). With novel image segmentation, ADCI has become a fully functional cytogenetic biodosimetry system. ADCI takes images from metaphase scanning systems,  selects high quality cells, identifies dicentric chromosomes, builds biodosimetry calibration curves, and estimates exposures.  ADCI fulfills the criteria established by the IAEA for accurate triage biodosimetry of a sample in less than an hour. The accuracy is comparable to an experienced cytogeneticist. Check out our online user manual: wiki.

We find and validate mutations and gene signatures that others cannot with advanced,  patented genomic bioinformatic technologies. Cytognomix continues our  long track record of creating technologies for genomic medicine. We anticipate and implement the needs of the molecular medicine and genomics communities.

Predict chemotherapy outcomes

Pharmacogenomic responses to chemotherapy drugs can be predicted by supervised machine learning of expression and copy number of relevant gene combinations. Since 2015,  CytoGnomix has used biochemical evidence to derive gene signatures from changes in gene expression in cell lines, which can subsequently be examined in patients that have been treated with the same drugs. We have derived signatures for 30 different commonly used drugs.  Try out out our online predictor:  https://chemotherapy.cytognomix.com. 

Quantifying responses to ionizing radiation with gene expression signatures.

Gene signatures derived by machine learning have low error rates in externally validated, independent radiation exposed data. They exhibit high specificity and granularity for dose estimation in humans and mice.  These signatures can be designed to avoid the effects of confounding, comorbidities which can reduce specificity for detecting radiation exposures. See: https://f1000research.com/articles/7-233/v2

Single copy genomic technologies

Latest Posts

June 3, 2017. Presentation at Variant Detection 2017

Peter Rogan will be presenting “A Unified Framework For Prioritization Of Variants Of Uncertain Significance In Hereditary Breast And Ovarian Cancer” at Variant Detection 2017 in Santiago de Compostela Spain on June 5, 2017. Coauthors are Eliseos Mucaki1, Natasha Caminsky1, Ruipeng Lu1, Joan Knoll1,2 and Peter Rogan1,2. 1University of Western Ontario, 2CytoGnomix Inc. Abstract: Purpose: […]

June 1, 2017. Products delivered under the Build in Canada Innovation Program

CytoGnomix has delivered the Automated Dicentric Chromosome Identifier and Dose Estimator system to the Healthy Environments and Consumer Safety Branch at Health Canada, Government of Canada and to the Biodosimetry laboratory at Canadian Nuclear Laboratories.  Each lab received two licensed versions of the product on a state of the art MSI portable computer  and two full days […]

May 22, 2017. Protocol on automated radiation biodosimetry accepted for publication

Our article: “Expedited radiation biodosimetry by automated dicentric chromosome identification and dose estimation” Ben Shirley 1^ , Yanxin Li 1^ , Joan H. M. Knoll 1,2 , and Peter K. Rogan 1,3 1 CytoGnomix, Departments of 2 Pathology and Laboratory Medicine and 3 Biochemistry, Western University, London, ON Canada has been accepted for publication in […]

May 4, 2017. CytoGnomix introducing new biodosimetry product

  CytoGnomix will be exhibiting at the 22nd Nuclear Medical Defense Conference, next week (May 8th to 11th 2017) in Munich, Germany. We will be introducing our biodosimetry product, the Automated Dicentric Chromosome Identifier and Dose Estimator (ADCI) at the meeting. We will also be presenting a poster on novel, patent pending methods to automatically […]

April 8, 2017. Presentation about chemotherapy outcome prediction

Rogan PK, Mucaki EJ, Baranova K, Dorman S, Knoll JHM. Predicting responses to chemotherapies by biochemically-inspired machine learning. Innovative Approaches to Optimal Cancer Care in Canada, Canadian Partnership against Cancer, Toronto, Apr. 6-8, 2017. (Link to abstract)

March 31, 2017. New preprint on increased accuracy in radiation biodosimetry

Accurate Cytogenetic Biodosimetry Through Automation Of Dicentric Chromosome Curation And Metaphase Cell Selection Jin Liu, Yaking Li, Ruth Wilkins, Farrah Flegal, Joan H. M. Knoll, Peter K. Rogan. bioRxiv, doi: https://doi.org/10.1101/120410 Abstract: Software to automate digital pathology relies on image quality and the rates of false positive and negative objects in these images. Cytogenetic biodosimetry […]

February 27, 2017. CytoGnomix finalizes contract with Government of Canada

CytoGnomix has finalized our contract with Public Works Government Services Canada under the Build in Canada Innovation Program. This agreement licenses the Automated Dicentric Chromosome Identifier (ADCI) to the Consumer and Clinical Radiation Protection Bureau at Health Canada and Canadian Nuclear Laboratories and provides on-site training to these labs. These biodosimetry reference labs will test […]